In Brief: Amersham Pharmacia Biotech
This article was originally published in The Gray Sheet
Executive Summary
Amersham Pharmacia Biotech: Aims to expand its gene mutation analysis business via acquisition of an exclusive worldwide license from Avitech Diagnostics enabling commercialization of products based on Avitech's EMD proprietary gene mutation scanning technology for research and diagnostic use. Under the terms of the deal, Amersham Pharmacia Biotech "will establish partnership programs with diagnostic product companies, based on EMD and other proprietary technologies," the firm states. Avitech retains rights to provide genome research, pharmacogenomic and diagnostic services based on the EMD technology...